Universe Pharmaceuticals INC
corporate_fare Company Profile
Universe Pharmaceuticals INC (NASDAQ:UPC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 11 items for UPC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-29, rated 8/10. Across its 11 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for UPC spans F-3, 6-K, SCHEDULE 13D, 20-F.
Recent high-impact activity:
- Universe Pharmaceuticals Files $200M Shelf and Registers 87% of Outstanding Shares for Resale
- Universe Pharmaceuticals Seeks Shareholder Approval for 1-for-10 Reverse Split to Regain Nasdaq Compliance
- Universe Pharmaceuticals closes $10.75M Best Praise acquisition, issuing 4.38M shares
- Universe Pharma Posts $9M Revenue, $1.6M Loss; Unveils $10.75M All-Stock Deal
- Universe Pharmaceuticals to Acquire Best Praise for $10.75M in Stock, Causing Over 1000% Dilution
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 41,937 shares in UPC as of the October 30, 2026 settlement, a 38.4% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 33.9% of UPC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for UPC, detected from its recent SEC filings.
$200M Universal Shelf Registered · 87% of Outstanding Shares Registered for Resale
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
UPC files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.